Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $3.4 million.

  • Orchestra BioMed Holdings' Change in Accured Expenses rose 17694.81% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 1403.93%. This contributed to the annual value of $3.0 million for FY2024, which is 194758.62% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Change in Accured Expenses of $3.4 million as of Q3 2025, which was up 17694.81% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Change in Accured Expenses ranged from a high of $3.7 million in Q2 2024 and a low of -$1.8 million during Q1 2023
  • Moreover, its 4-year median value for Change in Accured Expenses was $668000.0 (2023), whereas its average is $717733.3.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Change in Accured Expenses tumbled by 98861.39% in 2023 and then surged by 37830.55% in 2024.
  • Orchestra BioMed Holdings' Change in Accured Expenses (Quarter) stood at $1.1 million in 2022, then crashed by 53.4% to $493000.0 in 2023, then plummeted by 244.42% to -$712000.0 in 2024, then skyrocketed by 579.21% to $3.4 million in 2025.
  • Its Change in Accured Expenses was $3.4 million in Q3 2025, compared to $1.1 million in Q2 2025 and -$202000.0 in Q1 2025.